Pegaspargase

Generic Name: Pegaspargase

Brand Names: Oncaspar

Drug Type: Biotech

Chemical Formula: -

CAS Number: 130167-69-0

Unique Ingredient Identifier: 7D96IR0PPM

Background: Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synt...

Indication: Pegaspargase is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with 1) first-line acute lymphoblastic leukemia or 2) acute lymphoblastic leukemia and hypersensitivity to asparaginase.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL)

Associated Therapies: -

Clinical Trials

A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

Phase 1

Withdrawn

Conditions: Acute Leukemias
Acute Leukemia of Ambiguous Lineage
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia

Interventions: Drug: JNJ-75276617
Drug: Fludarabine
Drug: Cytarabine
Drug: Intrathecal Chemotherapy
Drug: Dexamethasone
Drug: Vincristine
Drug: Pegaspargase

First Posted Date: 2022-08-30

Last Posted Date: 2024-08-22

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT05521087

Locations: 🇺🇸
Memorial Sloan Kettering, New York, New York, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

and more 8 locations

Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL

Phase 2

Recruiting

Conditions: Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
Early-stage
High-Risk Cancer

Interventions: Drug: Anti-PD-1 monoclonal antibody
Drug: Pegaspargase
Drug: Gemcitabine
Drug: Oxaliplatin
Radiation: Involved site radiotherapy

First Posted Date: 2022-02-24

Last Posted Date: 2022-02-24

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 54

Registration Number: NCT05254899

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

Phase 1

Active, not recruiting

Conditions: Refractory Acute Lymphoblastic Leukemia
Relapsed Acute Lymphoblastic Leukemia

Interventions: Drug: Venetoclax
Drug: Navitoclax
Drug: Dexamethasone
Drug: Vincristine
Drug: Calaspargase Pegol
Drug: Dasatinib
Drug: Leucovorin
Drug: Cytarabine
Drug: Intrathecal Triples
Biological: Blinatumomab
Drug: Pegaspargase
Drug: Methotrexate
Drug: Erwinia asparaginase
Drug: Mercaptopurine
Drug: Cyclophosphamide
Drug: Etoposide
Radiation: Radiation

First Posted Date: 2022-01-14

Last Posted Date: 2024-11-26

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 35

Registration Number: NCT05192889

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

Phase 1

Recruiting

Conditions: B Acute Lymphoblastic Leukemia
Ph-Like Acute Lymphoblastic Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Daunorubicin Hydrochloride
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Pegaspargase
Drug: Prednisone
Drug: Venetoclax
Drug: Vincristine Sulfate

First Posted Date: 2021-12-15

Last Posted Date: 2024-10-26

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 24

Registration Number: NCT05157971

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Phase 2

Conditions: Extranodal NK/T-cell Lymphoma

Interventions: Drug: Gemcitabine
Drug: Pegaspargase
Drug: Etoposide
Drug: Dexamethasone

First Posted Date: 2021-06-08

Last Posted Date: 2021-06-08

Lead Sponsor: Beijing Tongren Hospital

Target Recruit Count: 15

Registration Number: NCT04917250

Locations: 🇨🇳
Beijing Tongren Hospital, Beijing, China

Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL

Phase 2

Not yet recruiting

Conditions: Extranodal NK/T-cell Lymphoma, Nasal Type

Interventions: Drug: Pegaspargase
Drug: Anti-PD-1 monoclonal antibody
Radiation: Definitive intensity-modulated radiotherapy (IMRT)

First Posted Date: 2020-12-21

Last Posted Date: 2020-12-21

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 30

Registration Number: NCT04676789

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Please Select, China

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Phase 2

Suspended

Conditions: Down Syndrome
Recurrent B Acute Lymphoblastic Leukemia

Interventions: Procedure: Biospecimen Collection
Radiation: 3-Dimensional Conformal Radiation Therapy
Biological: Blinatumomab
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Cytarabine
Drug: Dexamethasone
Drug: Calaspargase Pegol
Drug: Hydrocortisone Sodium Succinate
Procedure: Lumbar Puncture
Drug: Methotrexate
Biological: Nivolumab
Drug: Mercaptopurine
Drug: Pegaspargase
Drug: Pegcrisantaspase
Drug: Vincristine Sulfate

First Posted Date: 2020-09-14

Last Posted Date: 2024-10-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 300

Registration Number: NCT04546399

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Corewell Health Dearborn Hospital, Dearborn, Michigan, United States
🇺🇸
Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids, Michigan, United States

and more 200 locations